Pennant Investors’s Kyntra Bio KYNB Stock Holding History

Pennant Investors’s Portfolio KYNB Stock Details KYNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-30,736	Closed	-$686K	–	31
2024 Q2	$686K	Hold	30,736	–	–	0.18%	20
2024 Q1	$1.81M	Hold	30,736	–	–	0.45%	13
2023 Q4	$681K	Buy	+30,736	New	+$464K	0.15%	13

Other funds holding KYNB

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

GFG Capital Miami, Florida $363M AUM 45.53% 1-Year Est. Return

Pennant Investors's KYNB Position: Q3 2024 in Review

Pennant Investors sold out of Kyntra Bio (KYNB) in Q3 2024, closing a stake of 30,736 shares — an estimated $686K sold.

Pennant Investors first reported a position in KYNB in Q4 2023 and held it in 3 quarters. The position peaked at $1.81M in Q1 2024. 70 funds tracked by Wall St. Rank hold KYNB as of Q3 2024.

Pennant Investors reported no remaining Kyntra Bio position as of Q3 2024 after selling out during the quarter.
Pennant Investors sold 30,736 Kyntra Bio shares in Q3 2024, an estimated $686K.
Pennant Investors first reported a position in Kyntra Bio in Q4 2023 and held it in 3 quarters.
Pennant Investors's Kyntra Bio position peaked at $1.81M in Q1 2024.
70 funds tracked by Wall St. Rank held Kyntra Bio as of Q3 2024.

Based on Pennant Investors's 13F filing for Q3 2024, filed 14 Nov 2024.